secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001618835-23-000018
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem reduces workforce 39%, cuts CEO pay 40% to reach cash flow breakeven by year-end 2023
--------------------------------------------------------------------------------

- 39% reduction in payroll expenses via salary cuts, elimination of 8 positions including Chief Commercial Officer.
- CEO base salary reduced by 40% to ~$520K for remainder of FY 2023; other execs cut 20% vs prior year.
- Annualized cost savings of ~$4.3M; one-time pre-tax charges of ~$0.1M for severance and benefits.
- Three sales territories consolidated; RIF expected to be substantially complete by Q1 2023.
- Goal to reach cash flow break even by year-end 2023; company cites need to preserve capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000161883523000018/0001618835-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000161883523000018/evfm-20230317.htm
  HTML page:      https://secwatch.observer/filing/0001618835-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer